Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.

被引：6
|
作者：
Zhou, Ai-Ping
Bai, Yuxian
Song, Van
Li, Hangzhong
Xie, Xiaodong
Ren, Xiu-Bao
Ye, Dingwei
Liu, Jiyan
Luo, Hong
Bai, Xianzhong
Qin, Shukui
Fu, Cheng
Wang, Jinwan
Ma, Jianhui
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Heilongjiang, Peoples R China
[3] Peking Union Med Coll Hosp, Beijing, Peoples R China
[4] Gen Hosp Shenyang Mil Reg, Shenyang, Liaoning, Peoples R China
[5] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Abdominal Canc, Ctr Canc, Chengdu, Sichuan, Peoples R China
[8] Chongqing Canc Hosp, Chongqing, Peoples R China
[9] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[10] Nanjing Bayi Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
[11] Liaoning Canc Hosp Inst, Shenyang, Liaoning, Peoples R China
[12] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e16082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16082
引用
收藏
页数：2
相关论文
共 50 条
  • [41] AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium
    Sridhar, Srikala S.
    Mackenzie, Mary J.
    Hotte, Sebastien J.
    Mukherjee, Som D.
    Murray, Nevin
    Tannock, Ian F.
    Haider, Masoom A.
    Chen, Eric X.
    Wang, Lisa
    Srinivasan, Ranuka
    Ivy, S. Percy
    Moore, Malcolm J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3337S - 3338S
  • [42] Phase I trial of sunitinib (S) and temsirolimus (T) in metastatic renal cell carcinoma (mRCC)
    Campbell, Matthew T.
    Millikan, Randall E.
    Altinmakas, Emre
    Xiao, Lianchun
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [43] Phase II efficacy trial of pazopanib in nonclear cell metastatic renal cell cancer (mRCC): PINCR
    Costello, Brian Addis
    Thai Huu Ho
    Burbano, Gabriela Perez
    Hillman, David W.
    Quevedo, Fernando
    Pitot, Henry C.
    Pagliaro, Lance C.
    Bryce, Alan Haruo
    Tan, Winston
    Joseph, Richard Wayne
    Leibovich, Bradley C.
    Castle, Erik P.
    Dronca, Roxana Stefania
    Kohli, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [44] A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
    Ornstein, Moshe C.
    Wood, Laura S.
    Hobbs, Brian P.
    Allman, Kimberly D.
    Martin, Allison
    Bevan, Michael
    Gilligan, Timothy D.
    Garcia, Jorge A.
    Rini, Brian, I
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [45] Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Molina, A. M.
    Feldman, D. R.
    Ginsberg, M. S.
    Fischer, P.
    Trinos, M. J.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [46] Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
    Escudier, Bernard
    Barthelemy, Philippe
    Ravaud, Alain
    Negrier, Sylvie
    Needle, Michael N.
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [47] ORAL THALIDOMIDE IN PROGRESSING METASTATIC RENAL CELL CARCINOMA (MRCC): A PROSPECTIVE PHASE II STUDY
    Caserta, Claudia
    Bracarda, Sergio
    Ludovini, Vienna
    Darwish, Samir
    Pistola, Lorenza
    Tofanetti, Francesca M.
    Marrocolo, Francesca
    Tonato, Maurizio
    ANNALS OF ONCOLOGY, 2004, 15 : 91 - 92
  • [48] Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC).
    Choueiri, T. K.
    Dreicer, R.
    Rini, B. I.
    Elson, P.
    Garcia, J.
    Mekhail, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 226S - 226S
  • [49] Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results
    Tomasello, L.
    Sertoli, M. R.
    Rubagotti, A.
    Guglielmini, P.
    Tacchini, L.
    Bedognetti, D.
    Ricci, F.
    Sanguineti, S.
    Cassata, A.
    Boccardo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial.
    Thompson, D. S.
    Greco, F. A.
    Spigel, D. R.
    Sosman, J. A.
    Burkett, E.
    O'Rourke, T. J.
    Hart, L.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 240S - 240S
12345